People v. Shreck

22 P.3d 68, 2001 WL 403466
CourtSupreme Court of Colorado
DecidedMay 14, 2001
Docket00SA105
StatusPublished
Cited by841 cases

This text of 22 P.3d 68 (People v. Shreck) is published on Counsel Stack Legal Research, covering Supreme Court of Colorado primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
People v. Shreck, 22 P.3d 68, 2001 WL 403466 (Colo. 2001).

Opinion

Justice RICE

delivered the Opinion of the Court.

The prosecution in this case initiated this original proceeding pursuant to C.A.R. 21, seeking relief from a trial court order granting the defendant's motion to bar DNA evi-denee. The trial court held that under Frye v. United States, 293 F. 1013, 1014 (D.C.Cir.1923), the multiplex technique employed by the commercial testing kits used by the Colorado Bureau of Investigation ("CBI") in 1999 was not yet generally accepted at that time by the relevant scientific community. Thus, the trial court ruled that the DNA evidence at issue in this case, which was derived from those kits, was not admissible against the defendant. We issued a rule to show cause why the trial court's order should not be vacated, and the defendant responded.

We now hold that CRE 702, rather than Frye, governs a trial court's determination as to whether scientific or other expert testimony should be admitted. Such an inquiry should focus on the reliability and relevance of the proffered evidence and requires a determination as to (1) the reliability of the scientific principles, (2) the qualifications of the witness, and (8) the usefulness of the testimony to the jury. We also hold that when a trial court applies CRE 702 to determine the reliability of scientific evidence, its inquiry should be broad in nature and consider the totality of the circumstances of each specific case. In doing so, a trial court may consider a wide range of factors pertinent to the case at bar. The factors mentioned in Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579, 593-94, 113 S.Ct. 2786, 125 L.Ed.2d 469 (1993), and by other courts may or may not be pertinent, and thus are not necessary to every CRE 702 inquiry. In light of this liberal inquiry, a trial court should also apply its discretionary authority under CRE 403 to ensure that the probative value of the evidence is not substantially outweighed by unfair prejudice. Finally, we hold that under CRE 702, a trial court must issue specific findings as it applies the CRE 702 and 408 analyses.

We further hold that under CRE 702, the multiplex testing techniques at issue in this case were sufficiently reliable to warrant admission of the DNA evidence derived from their use. Accordingly, we make the rule absolute and direct the trial court to vacate its order barring such evidence.

I. SCIENTIFIC BACKGROUND

We described the scientific principles and techniques underlying DNA typing in Fishback v. People, 851 P.2d 884, 885 (Colo.1993). We now review those principles and techniques in the context of the particular method of DNA typing at issue in this case.

Within the nucleus of each human cell are twenty-three pairs of chromosomes composed of deoxyribonucleie acid ("DNA"), which contains the coded information that *71 provides the genetic material determining the physical structure and characteristics for each individual. No two individuals, except identical twins, have the same DNA structure. A DNA molecule is shaped like a double helix, which resembles a twisted ladder. The sides of the ladder are composed of phosphate and sugar molecules and the rungs are composed of a pair of organic compounds called bases. Two bases form a single rung called a base pair. The order in which these base pairs appear in the ladder is the genetic code of that individual. There are approximately three billion base pairs in a human being, 99% of which are the same in each person. However, certain sections of DNA vary from person to person. These areas are called polymorphisms. DNA typing concerns the examination of two types of polymorphisms: length and sequence.

One method of detecting and measuring length variations is called restriction fragment length polymorphism ("RFLP") analysis. The RFLP procedure isolates DNA in a blood sample so that certain polymorphisms can be located in the DNA. RFLP is a widely accepted and scientifically validated method of testing that has generally been found to be admissible in state and federal courts. United States v. Hicks, 103 F.3d 837, 846-47 (9th Cir.1996); United States v. Chischilly, 30 F.3d 1144, 1153-56 (9th Cir.1994); United States v. Lowe, 954 F.Supp. 401, 416 (D.Mass.1996); Fishback, 851 P.2d at 893.

Polymerase chain reaction ("PCR") is a process by which DNA fragments too small to be suitable for RFLP analysis can be analyzed. Under the PCR process, these DNA fragments are duplicated many times, thus allowing very small samples to be accurately tested. PCR also permits testing in a relatively short time in comparison to prior methods that required the decay of radioactive materials. Finally, unlike RFLP testing, which destroys the sample, PCR processing allows a technician to reproduce and verify test results by creating a larger sample for testing.

The D1S80 test is a hybrid of the PCR and RFLP methods. It detects fragment length polymorphisms onee the DNA fragment has been amplified through the PCR procedure.

Another form of PCR testing involves the use of locations on the DNA strand containing short tandem repeats ("STR") of baseline patterns. STR testing reveals length differences between chromosomes on different people with the same base pair sequences. There are thirteen locations at which the number of STRs are known to vary from person to person. Thus, if all thirteen locations of the known and questioned sample are identical, a match is considered to have been made.

When STR loci are amplified through the PCR process separately and run on a separate gel, the system is called "monoplex." Multiplex systems add more than one set of PCR primers to a reaction so as to be able to amplify several loci together and run them simultaneously. Monoplex systems and multiplex systems that amplify and run three loci simultaneously, ("triplex"), have been in use for many years.

The commercial kits used to perform the STR testing at issue in this case were manufactured by Perkins Elmer Biosystems ("PE"). These kits, called AmpFLSTR Pro-filer Plus ("Profiler Plus") and AmpFLSTR Coffler ("Cofiler"), employ a combination six-plex and nineplex system that is able to read all thirteen locations at the same time. 1 In January 1999, when they were used in this case, the kits were relatively new to the market.

II. FACTS AND PROCEDURAL HISTORY

The defendant in this case has been in and out of jail since 1983. In April 1990, he was on parole and living in the Boulder area when a University of Colorado student was sexually assaulted. Although a rape kit was used on the victim, the crime was never solved. In 1998, the case was reopened and the CBI performed a DNA analysis using *72 several PCR-based tests on the rape kit samples. A 1991 blood sample from the defendant was analyzed against the rape kit results. The CBI concluded that the probability that the contributor to the rape kit sample was not the defendant was one in 11,000. An analysis of a new blood sample from the defendant revealed identical results.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Mukendi v. Schrock
Colorado Court of Appeals, 2025
v. Ornelas-Licano —
2020 COA 62 (Colorado Court of Appeals, 2020)
v. Vidauri
2019 COA 140 (Colorado Court of Appeals, 2019)
v. Genrich
2019 COA 132 (Colorado Court of Appeals, 2019)
State of Tennessee v. Quintis McCaleb
Tennessee Supreme Court, 2019
Lorenzen v. Pinnacol Assurance
2019 COA 54 (Colorado Court of Appeals, 2019)
Tisch v. Tisch
2019 COA 41 (Colorado Court of Appeals, 2019)
v. Cooper
2019 COA 21 (Colorado Court of Appeals, 2019)
People v. Garrison
2017 COA 107 (Colorado Court of Appeals, 2017)
Estate of Ford v. Eicher
250 P.3d 262 (Supreme Court of Colorado, 2011)
Maloney v. Brassfield
251 P.3d 1097 (Colorado Court of Appeals, 2010)
People v. Tucker
232 P.3d 194 (Colorado Court of Appeals, 2009)
People v. Rector
226 P.3d 1170 (Colorado Court of Appeals, 2009)
People Ex Rel. Mm, Jr.
215 P.3d 1237 (Colorado Court of Appeals, 2009)
Estate of Ford v. Eicher
220 P.3d 939 (Colorado Court of Appeals, 2008)
People v. Jimenez
217 P.3d 841 (Colorado Court of Appeals, 2008)
People v. Laurent
194 P.3d 1053 (Colorado Court of Appeals, 2008)
Luster v. Brinkman
205 P.3d 410 (Colorado Court of Appeals, 2008)
People v. Muniz
190 P.3d 774 (Colorado Court of Appeals, 2008)
Golob v. People
180 P.3d 1006 (Supreme Court of Colorado, 2008)

Cite This Page — Counsel Stack

Bluebook (online)
22 P.3d 68, 2001 WL 403466, Counsel Stack Legal Research, https://law.counselstack.com/opinion/people-v-shreck-colo-2001.